Double Trouble for Lupus Nephritis: Belimumab Meets the Calcineurin Inhibitor (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0798; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Current guidelines recommend glucocorticoids with immunosuppressive therapy and support add-on use of either belimumab or calcineurin inhibitors (CNIs), such as voclosporin or tacrolimus...All patients were treated with background standard-of-care therapy consisting of mycophenolate mofetil, prednisone taper, and hydroxychloroquine (HCQ)...Trials are much needed to evaluate this approach. Patient Demographics and Treatment Response"
Chronic Kidney Disease • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Sarah Turner; Brian Ruiz; Joanne Ike; Amr Habbach; Sonia J. Manocha; Swati Arora
|